For Q4 2025, the company reported a net loss of 364892000 driven by higher operating expenses, including 294943000 in R&D and 66683000 in G&A. It ended the quarter with 2025679000 in cash, cash equivalents and marketable securities.

Revolution Medicines reported a net loss driven by high R&D and G&A expenses, supported by a strong cash position from a funding agreement.

Revolution Medicines continued executing its clinical strategy in Q1 2025 with substantial R&D spend and new clinical data disclosures, while maintaining a strong cash position of $2.1 billion.

Revolution Medicines reported no revenue in Q4 2024, reflecting the termination of its Sanofi collaboration. The company posted a net loss of $194.6 million, driven by increased R&D expenses of $188.1 million. Cash, cash equivalents, and marketable securities reached $2.3 billion following an $823 million public equity offering. The company continues advancing its RAS(ON) inhibitors, with multiple Phase 3 trials underway.

Revolution Medicines reported its Q3 2024 financial results, highlighting the progress of its clinical-stage RAS(ON) inhibitors, including RMC-6236 and RMC-9805, and the initiation of a Phase 3 pivotal trial for RMC-6236 in metastatic pancreatic cancer. The company's cash position remains strong, enabling operations into 2027.

Revolution Medicines reported its Q2 2024 financial results, with a net loss of $133.2 million and no revenue, as compared to a net loss of $98.3 million and $3.8 million in revenue for the same period in 2023. The company's cash, cash equivalents, and marketable securities totaled $1.59 billion as of June 30, 2024. The company is progressing with its RAS(ON) inhibitor programs, including RMC-6236, RMC-6291, and RMC-9805, and is planning for a Phase 3 study for RMC-6236 in pancreatic cancer.

Revolution Medicines reported a net loss of $116.0 million for the quarter ended March 31, 2024, compared to a net loss of $68.1 million for the quarter ended March 31, 2023. As of March 31, 2024, cash, cash equivalents, and marketable securities totaled $1.70 billion.

Revolution Medicines reported a net loss of $161.5 million for the quarter ended December 31, 2023, compared to a net loss of $56.5 million for the quarter ended December 31, 2022. The company's cash, cash equivalents, and marketable securities were $1.85 billion as of December 31, 2023. The company expects full year 2024 GAAP net loss to be between $480 million and $520 million.

Revolution Medicines announced its financial results for the quarter ended September 30, 2023. Promising clinical data for RMC-6236 and RMC-6291 was presented at AACR-NCI-EORTC and ESMO Meetings. The acquisition of EQRx, Inc. is expected to close later this month.

Revolution Medicines reported second quarter 2023 financial results, highlighting clinical updates for RMC-6236 and RMC-6291, and announced the acquisition of EQRx, Inc., expected to add more than $1 billion to the balance sheet. The company's cash, cash equivalents, and marketable securities were $909.5 million as of June 30, 2023. Total revenue was $3.8 million, and net loss was $98.3 million for the quarter.